Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
Novartis has teamed up with celebrity interior designer Nate Berkus to launch My Home in Sight, a program that aims to raise awareness of the daily impact of wet age-related macular degeneration and empower those living with wet AMD and their caregivers to make simple, functional changes to support safety and independence at home.
Kala Pharmaceuticals Inc. received a complete response letter from the U.S. Food and Drug Administration regarding the company’s new drug application for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
Ophthalmic medical technology and pharmaceutical company Glaukos Corp. will acquire hybrid ophthalmic pharma and medical tech company Avedro Inc. in an all-stock transaction.
Allergan Plc – which is being bought by AbbVie Inc. for $63 billion – beat second-quarter 2019 profit estimates and raised the company’s full-year revenue forecast, helped by demand for the dry eye drug Restasis and aesthetics product Juvederm.
The U.S. Food and Drug Administration approved Celgene Corp.’s Otezla (apremilast) 30 mg twice daily for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.
Novartis is buying the projected blockbuster dry-eye drug Xiidra from Takeda Pharmaceutical for up to $5.3 billion.
I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.
Novartis announced that the U.S. Food and Drug Administration accepted the company’s Biologics License Application for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration.